Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Ectoin Lozenges (EHT02) in the Treatment of Oropharyngeal Allergic Symptoms

NCT: NCT03975257 · COMPLETED

NCT IDNCT03975257
StatusCOMPLETED
Start Date2019-02-04
Completion2019-09-12
SponsorBitop AG (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this multicentric, prospective, randomised, controlled study (§23b German Act on Medical Devices (MPG)) is to investigate the efficacy of Ectoin Lozenges (EHT02) in treatment and prevention of oropharyngeal allergic symptoms.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑